Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Clinical trial NCT05756166 · TERMINATED

Trial details

NCT number: NCT05756166
Sponsor: Roswell Park Cancer Institute
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Triple-Negative Breast Carcinoma Unresectable Triple-Negative Breast Carcinoma

Start date: 2024-02-16
Primary completion: 2025-04-08
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.